Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Change in Accured Expenses: 2019-2025

Historic Change in Accured Expenses for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to -$2.0 million.

  • C4 Therapeutics' Change in Accured Expenses fell 148.30% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.1 million, marking a year-over-year decrease of 6805.00%. This contributed to the annual value of -$1.3 million for FY2024, which is 196.28% down from last year.
  • According to the latest figures from Q3 2025, C4 Therapeutics' Change in Accured Expenses is -$2.0 million, which was down 421.37% from $627,000 recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' Change in Accured Expenses ranged from a high of $5.2 million in Q4 2023 and a low of -$7.7 million during Q1 2024.
  • In the last 3 years, C4 Therapeutics' Change in Accured Expenses had a median value of -$733,000 in 2023 and averaged -$733,545.
  • Examining YoY changes over the last 5 years, C4 Therapeutics' Change in Accured Expenses showed a top increase of 669.17% in 2024 and a maximum decrease of 426.07% in 2024.
  • Quarterly analysis of 5 years shows C4 Therapeutics' Change in Accured Expenses stood at $2.1 million in 2021, then rose by 26.09% to $2.7 million in 2022, then spiked by 92.50% to $5.2 million in 2023, then decreased by 23.29% to $4.0 million in 2024, then slumped by 148.30% to -$2.0 million in 2025.
  • Its Change in Accured Expenses stands at -$2.0 million for Q3 2025, versus $627,000 for Q2 2025 and -$6.7 million for Q1 2025.